Table 2 Mental health and metabolic profiles at baseline and after the 12-week intervention in women with polycystic ovary syndrome that received either probiotic plus selenium supplements or placeboa
Variables | Placebo group (n = 30) | Probiotic plus selenium group (n = 30) | Difference in outcome measures between probiotic plus selenium and placebo groupsa | |||
|---|---|---|---|---|---|---|
Baseline | Week 12 | Baseline | Week 12 | β (95% CI) | Pb | |
BDI total scores | 15.6 ± 4.4 | 15.3 ± 4.7 | 15.5 ± 4.0 | 14.4 ± 3.7 | −0.76 (−1.26, − 0.26) | 0.003 |
GHQ scores | 45.4 ± 8.1 | 44.6 ± 8.2 | 44.2 ± 7.3 | 42.4 ± 6.7 | −1.15 (− 1.97, −0.32) | 0.007 |
DASS scores | 86.3 ± 13.1 | 85.1 ± 12.9 | 85.1 ± 11.2 | 82.5 ± 10.9 | −1.49 (−2.59, −0.39) | 0.009 |
Total testosterone (ng/mL) | 1.3 ± 0.5 | 1.3 ± 0.4 | 1.4 ± 0.7 | 1.1 ± 0.6 | −0.26 (− 0.51, − 0.02) | 0.03 |
SHBG (nmol/L) | 40.3 ± 17.5 | 40.4 ± 18.3 | 47.1 ± 19.7 | 49.5 ± 22.1 | 1.82 (−1.77, 5.42) | 0.31 |
mF-G scores | 13.0 ± 3.7 | 13.0 ± 3.6 | 14.5 ± 3.2 | 14.0 ± 2.9 | −0.43 (−0.74, − 0.11) | 0.008 |
hs-CRP (mg/L) | 2.5 ± 1.6 | 2.7 ± 1.5 | 2.4 ± 1.5 | 2.0 ± 1.5 | −0.58 (− 0.97, − 0.19) | 0.004 |
NO (μmol/L) | 36.5 ± 3.8 | 36.8 ± 4.0 | 36.6 ± 2.3 | 37.8 ± 3.5 | 0.94 (−0.65, 2.54) | 0.24 |
TAC (mmol/L) | 909.9 ± 110.8 | 909.4 ± 122.7 | 933.3 ± 59.8 | 1012.9 ± 69.4 | 84.76 (48.08, 121.44) | < 0.001 |
GSH (μmol/L) | 496.4 ± 88.1 | 497.8 ± 88.3 | 528.3 ± 88.3 | 552.9 ± 83.1 | 26.78 (4.33, 49.23) | 0.02 |
MDA (μmol/L) | 2.4 ± 0.5 | 2.6 ± 0.7 | 2.8 ± 0.2 | 2.5 ± 0.2 | −0.29 (−0.56, −0.02) | 0.03 |